Clinical trials / NCT05496465
NCT05496465Phase 2Completed

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

Study sponsor: ARS Pharmaceuticals, Inc. · SPRY

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2024-02-29Actual
Enrollment · participants21Actual
Source updated2026-04-07Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 2 fields changed

Primary outcomes · main study measures

Text edit · unverified significance
− Previous value

measure: Effect of ARS-1 versus placebo based on a patient reported pruritus/hive score

+ Updated value

measure: Effect of ARS-1 Versus Placebo Based on a Patient Reported Pruritus/Hive Score

The saved outcome text may be shortened. Check the source for full wording.

Enrollment · participant count

Recorded edit
− Previous value

count: 24; type: ACTUAL

+ Updated value

count: 21; type: ACTUAL

Check registry source